Clinical and Preclinical Evidence for a BALIMONT Multistrain Platform in Respiratory Mucosal Barrier Support
International Journal of Agriculture and Food Sciences Research · 29.04.2026 · 4 (1) · 112-117
DOI: 10.62051/ijafsr.v4n1.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Agriculture and Food Sciences Research, online erschienen am 29.04.2026. Verfasst von Anas Ziraoui und 2 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
We integrated the reported BALIMONT platform data with published clinical-trial evidence relevant to respiratory mucosal immunity, upper respiratory tract infection (URTI) prevention, and gut–lung-axis signaling. The source platform combines Lacticaseibacillus rhamnosus DSM 20021, Lactobacillus acidophilus DSM 20079, and Bifidobacterium bifidum DSM 20456 with 2'-fucosyllactose, low-molecular-weight sodium hyaluronate, and baicalin across three delivery formats: mucoadhesive microcapsules, a nebulized inhalation solution, and oral enteric freeze-dried tablets. Across the retained platform dataset, 24 h respiratory epithelial adhesion reached 86.7%, 78.3%, and 72.5% for the three BALIMONT examples versus 21.6% for the comparator; respiratory secretory IgA increased by 38.9%, 32.4%, and 29.6% versus 7.5%; and 72 h microaerobic survival reached 91.3%, 87.6%, and 85.2% versus 34.7%. We then aligned these findings with published randomized trials showing that selected Lactobacillus- and Bifidobacterium-containing interventions shortened common-cold duration, reduced symptom burden, lowered school absenteeism or antibiotic use, or improved quality-of-life-related respiratory outcomes. Taken together, the evidence supports BALIMONT as a respiratory-barrier-oriented probiotic platform with plausible translational relevance, while also indicating that BALIMONT-specific randomized human validation is still needed.
Zitieren
APA
Ziraoui, A., Serrano, E., & Devereux, C. (2026). Clinical and Preclinical Evidence for a BALIMONT Multistrain Platform in Respiratory Mucosal Barrier Support. International Journal of Agriculture and Food Sciences Research, 4(1), 112-117. https://doi.org/10.62051/ijafsr.v4n1.12
Vancouver
Ziraoui A, Serrano E, Devereux C. Clinical and Preclinical Evidence for a BALIMONT Multistrain Platform in Respiratory Mucosal Barrier Support. International Journal of Agriculture and Food Sciences Research. 2026;4(1):112-117. doi:10.62051/ijafsr.v4n1.12
BibTeX
@article{Ziraoui2026,
author = {Ziraoui, Anas and Serrano, Eduardo and Devereux, Camille},
title = {Clinical and Preclinical Evidence for a BALIMONT Multistrain Platform in Respiratory Mucosal Barrier Support},
journal = {International Journal of Agriculture and Food Sciences Research},
year = {2026},
volume = {4},
number = {1},
pages = {112--117},
doi = {10.62051/ijafsr.v4n1.12}
}
EUVIMED